In recent trading session, DiaMedica Therapeutics Inc (NASDAQ:DMAC) saw 0.65 million shares changing hands at last check today with its beta currently measuring 1.24. Company’s recent per share price level of $4.23 trading at $0.25 or 6.28% at last check today assigns it a market valuation of $181.40M. That most recent trading price of DMAC’s stock is at a discount of -61.23% from its 52-week high price of $6.82 and is indicating a premium of 24.59% from its 52-week low price of $3.19. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.21 million shares which gives us an average trading volume of 185.33K if we extend that period to 3-months.
For DiaMedica Therapeutics Inc (DMAC), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.19 in the current quarter.
DiaMedica Therapeutics Inc (NASDAQ:DMAC) trade information
Upright in the green today for gaining 6.28%, in the last five days DMAC remained trading in the green while hitting it’s week-highest on Tuesday, 07/15/25 when the stock touched $4.23 price level, adding 4.08% to its value on the day. DiaMedica Therapeutics Inc’s shares saw a change of 18.16% in year-to-date performance and have moved 15.26% in past 5-day. DiaMedica Therapeutics Inc (NASDAQ:DMAC) showed a performance of 20.51% in past 30-days. Number of shares sold short was 1.23 million shares which calculate 10.88 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 8 to the stock, which implies a rise of 47.12% to its recent value today. Analysts have been projecting 7 as a low price target for the stock while placing it at a high target of 10. It follows that stock’s current price would drop -65.48% in reaching the projected high whereas dropping to the targeted low would mean a loss of -65.48% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 7.39% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -29.44% while estimates for its earnings growth in next 5 years are of -14.05%.
DiaMedica Therapeutics Inc (NASDAQ:DMAC)’s Major holders
Insiders are in possession of 26.28% of company’s total shares while institution are holding 35.99 percent of that, with stock having share float percentage of 48.82%. Investors also watch the number of corporate investors in a company very closely, which is 35.99% institutions for DiaMedica Therapeutics Inc that are currently holding shares of the company. COOPERMAN LEON G is the top institutional holder at DMAC for having 1.4 million shares of worth $4.13 million. And as of 2024-06-30, it was holding 3.6883 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 1.02 million shares on 2024-06-30. The number of shares represents firm’s hold over 2.6803 of outstanding shares, having a total worth of $3.0 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 857.67 shares of worth $3.68 million or 2.00% of the total outstanding shares. The later fund manager was in possession of 445.7 shares on Mar 31, 2025 , making its stake of worth around $1.91 million in the company or a holder of 1.04% of company’s stock.
